Larkspur Health Acquisition 

$22.5
22
+$0+0% Monday 21:59

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

1AprExpected
Q2 2024
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Next
-3.31
-1.61
0.09
1.79
Expected EPS
-0.3
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2021
2022
0Revenue
-1.79MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LSPR. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals focuses on creating new treatments for inflammatory diseases, directly competing with ZyVersa's inflammatory disease segment.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals develops therapies for inflammatory conditions, overlapping with ZyVersa's product pipeline.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences has a strong presence in the development of treatments for inflammatory and renal diseases, areas ZyVersa is targeting.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie has a diverse portfolio in immunology and inflammatory diseases, competing with ZyVersa's therapeutic areas.
AMGEN
AMGN
Mkt Cap160.66B
Amgen's focus on innovative therapeutics for inflammatory diseases places it in direct competition with ZyVersa.
Biogen
BIIB
Mkt Cap22.63B
Biogen's investment in novel therapies for neurological and inflammatory diseases makes it a competitor.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in the inflammatory disease space.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a broad range of products for inflammatory conditions, directly competing with ZyVersa's focus areas.
Novartis
NVS
Mkt Cap237.61B
Novartis AG engages in the research, development, and marketing of healthcare products, including treatments for inflammatory diseases.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in various therapeutic areas, including inflammation, competing with ZyVersa's development programs.

About

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
Show more...
CEO
Mr. Stephen C. Glover
Employees
7
Country
US
ISIN
US51724W1071

Listings

0 Comments

Share your thoughts

FAQ

What is Larkspur Health Acquisition stock price today?
The current price of LSPR is $22.5 USD — it has increased by +0% in the past 24 hours. Watch Larkspur Health Acquisition stock price performance more closely on the chart.
What is Larkspur Health Acquisition stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Larkspur Health Acquisition stocks are traded under the ticker LSPR.
What were Larkspur Health Acquisition earnings last quarter?
LSPR earnings for the last quarter are -0.07 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Larkspur Health Acquisition revenue for the last year?
Larkspur Health Acquisition revenue for the last year amounts to 0 USD.
What is Larkspur Health Acquisition net income for the last year?
LSPR net income for the last year is -1.79M USD.
How many employees does Larkspur Health Acquisition have?
As of April 02, 2026, the company has 7 employees.
In which sector is Larkspur Health Acquisition located?
Larkspur Health Acquisition operates in the Health Care sector.
When did Larkspur Health Acquisition complete a stock split?
Larkspur Health Acquisition has not had any recent stock splits.
Where is Larkspur Health Acquisition headquartered?
Larkspur Health Acquisition is headquartered in Weston, US.